References
- Word Health Organisation. Depression Fact Sheet. http://www.who.int/mediacentre/factsheets/fs369/en/.
- Therapeutic Goods Administration (TGA). Australian public assessment report for agomelatine. In: Administration DoHaATG, editor. Australia: Australian Government; 2010. p. 87.
- Servier Laboratories. Valdoxan – Product information 2016. http://www.servier.com.au/products.
- Persson HE, Sjoberg GK, Haines JA, Pronczuk de Garbino J. Poisoning severity score. Grading of acute poisoning. J Toxicol Clin Toxicol. 1998;36(3):205–13.
- Holliman BJ, Chyka PA. Problems in assessment of acute melatonin overdose. South Med J. 1997;90(4):451–3.
- Freiesleben SD, Furczyk K. A systematic review of agomelatine-induced liver injury. J Mol Psychiatry. 2015;3(1):4.
- Horgan D, Dodd S. Combination antidepressants: use by GPs and psychiatrists. Aust Family Phys. 2011;40(6):397–400.
- Agomelatine. Australian Prescriber. 2010;33(5):160–3.
- Wang X, Zhang D, Liu M, Zhao H, Du A, Meng L, et al. LC–MS/MS method for the determination of agomelatine in human plasma and its application to a pharmacokinetic study. Biomed Chromatogr. 2014;28(2):218–22.
- Kennedy SH, Eisfeld BS. Agomelatine and its therapeutic potential in the depressed patient. Neuropsychiatr Dis Treat. 2007;3(4):423–8.